Companies, institutions and data are cited as public industry context. These references do not imply partnership, endorsement, certification or a commercial relationship with our company.
What the source covers
The linked 2025 disclosure discusses China-based suppliers for parts of the supply chain, including chemical synthesis inputs.
Keep the scope clear
These independent sources do not establish a partnership with BLOPEP, certification of our products or approval of a particular batch. Follow the primary document for details and limitations.
Sources and verification scope
Eli Lilly and Company Form 10-K, fiscal year 2025 ↗
SEC · filing by Eli Lilly and Company
Source details (original language)
- Scope
- Lilly reports reliance on China-based suppliers for portions of its supply chain
- Document section
- Manufacturing and supply, p. 21; third-party supply chain risk factors
- Limitations
- Does not identify Bolang, peptide purchases from Bolang, partnership, endorsement or certification.
- Claim verification date
- 2026-09-09
Related reading
Eli Lilly and Company
Company documents and their place in the pharmaceutical supply chain.
Read details →